药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Rosoxacin
Saprisartan
Bromocriptine may decrease the antihypertensive activities of Saprisartan.
Rosoxacin
Epoprostenol
Bromocriptine may decrease the antihypertensive activities of Epoprostenol.
Rosoxacin
Rescinnamine
Bromocriptine may decrease the antihypertensive activities of Rescinnamine.
Rosoxacin
Bretylium
Bromocriptine may decrease the antihypertensive activities of Bretylium.
Rosoxacin
Trimethaphan
Bromocriptine may decrease the antihypertensive activities of Trimethaphan.
Rosoxacin
Pentolinium
Bromocriptine may decrease the antihypertensive activities of Pentolinium.
Rosoxacin
Deserpidine
Bromocriptine may decrease the antihypertensive activities of Deserpidine.
Rosoxacin
Omapatrilat
Bromocriptine may decrease the antihypertensive activities of Omapatrilat.
Rosoxacin
Somatostatin
The serum concentration of Bromocriptine can be increased when it is combined with Somatostatin.
Rosoxacin
Lanreotide
The serum concentration of Bromocriptine can be increased when it is combined with Lanreotide.
Rosoxacin
Pasireotide
The serum concentration of Bromocriptine can be increased when it is combined with Pasireotide.
Rosoxacin
Vapreotide
The serum concentration of Bromocriptine can be increased when it is combined with Vapreotide.
Rosoxacin
Levodopa
The risk or severity of hypotension and orthostatic hypotension can be increased when Bromocriptine is combined with Levodopa.
Orciprenaline
Oliceridine
The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Tubocurarine is combined with Oliceridine.
Orciprenaline
Remimazolam
The risk or severity of sedation can be increased when Tubocurarine is combined with Remimazolam.
Orciprenaline
Magnesium
Tubocurarine can cause a decrease in the absorption of Magnesium resulting in a reduced serum concentration and potentially a decrease in efficacy.
Orciprenaline
Lasmiditan
The risk or severity of adverse effects can be increased when Tubocurarine is combined with Lasmiditan.
Orciprenaline
Metoclopramide
The risk or severity of sedation can be increased when Metoclopramide is combined with Tubocurarine.
Orciprenaline
Cyclobenzaprine
The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Tubocurarine.
Orciprenaline
Esketamine
The risk or severity of adverse effects can be increased when Tubocurarine is combined with Esketamine.